363
Participants
Start Date
July 5, 2016
Primary Completion Date
March 9, 2018
Study Completion Date
December 26, 2018
Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Cobimetinib
Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Regorafenib
Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Cliniques Universitaires St-Luc, Brussels
Northern Cancer Institute, St Leonards
Sydney Adventist Hospital; Clinical Trial Unit, Sydney
Port Macquarie Base Hospital;North Coast Cancer Institute, Port Macquarie
Imeldaziekenhuis, Bonheiden
UZ Leuven Gasthuisberg, Leuven
Austin Health; Cancer Clinical Trial Centre, Heidelberg
Monash Medical Centre; Oncology, Clayton
Peninsula and South Eastern Haematology and Oncology Group, Frankston
GHdC Site Notre Dame, Charleroi
AZ Groeninge, Kortrijk
Memorial Sloan Kettering Cancer Center, New York
National Cancer Center, Gyeonggi-do
North Shore Hem Onc Associates, East Setauket
University of Pittsburgh Cancer Institute; Division of Medical Oncology, Pittsburgh
Istit. Naz. per la Ricerca sul Cancro - Az. Osped. S. Martino, Genoa
Georgetown University, Washington D.C.
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milan
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milan
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid
Hospital Clinico San Carlos; Servicio de Oncologia, Madrid
Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid
Hospital de Navarra; Servicio de Oncologia, Navarra
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville
Florida Cancer Specialists., St. Petersburg
Florida Cancer Specialists; SCRI, Fort Myers
Sarah Cannon Research Inst., Nashville
SCRI Tennessee Oncology Chattanooga, Chattanooga
A.O. Universitaria Policlinico Di Modena; Oncologia, Modena
Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia
Southdale Cancer Clinic U of M Medical Center, Fairview- Edina, Edina
A.O. Universitaria Pisana; Oncologia, Pisa
Chonnam National University Hwasun Hospital, Jeollanam-do
Ingalls Cancer Research Center, Harvey
Washington University School of Medicine, St Louis
IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia, San Giovanni Rotondo
INTEGRIS Cancer Inst of OK, Oklahoma City
MD Anderson Cancer Center, Houston
Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica, Napoli
City of Hope Comprehensive Cancer Center, Duarte
Medical Oncology Associates, Spokane
N.N.Burdenko Main Military Clinical Hospital; Oncology Dept, Moscow
Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk
BHI of Omsk region Clinical Oncology Dispensary, Omsk
Yale Cancer Center; Medical Oncology, New Haven
Tom Baker Cancer Centre-Calgary, Calgary
Cross Cancer Institute; Clinical Trials, Edmonton
BCCA-Vancouver Cancer Centre, Vancouver
The Ottawa Hospital, Ottawa
Sunnybrook Health Sciences Centre, Toronto
McGill University Health Center, Cedar Cancer Center, Montreal
Hopital du Sacre-Coeur, Montreal
CHU de Québec, Québec
Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong
Tuen Mun Hospital; Clinical Oncology, Hong Kong
Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin
Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy, Bydgoszcz
Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdansk
Szpitale Pomorskie Sp. z o. o., Gdynia
Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Krakow
Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii, Lodz
Seoul National University Hospital, Seoul
Asan Medical Center - Oncology, Seoul
Samsung Medical Center, Seoul
Yonsei University Health System/Severance Hospital, Seoul
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Birmingham Heartlands Hospital; Dept of Oncology, Birmingham
Royal Marsden Hospital - Fulham; Oncology Department, London
The Christie; GI Research Office, Manchester
Churchill Hospital; Department of Oncology, Oxford
Queen's Hospital, Romford
Weston Park Hospital; Cancer Clinical Trials Centre, Sheffield
Royal Marsden Hospital; Dept of Medical Oncology, Sutton
Hoffmann-La Roche
INDUSTRY